Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 738 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo (dextrose) Clear all

Conditions: Type 2 Diabetes
Interventions: decaff, caffcoff, caffeine, placebo; Other
Lead sponsor: Brooklyn College of the City University of New York; Other
Eligibility: 18 Years to 35 Years · Male only
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Type 2 Diabetes Mellitus
Interventions: LIK066, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Spinal Cord Injuries
Interventions: Caffeine, AIH, Placebo, SHAM; Drug · Other
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Prostatic Neoplasms
Interventions: Pembrolizumab, Enzalutamide, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 28
States / cities: Mobile, Alabama • Fullerton, California • Los Angeles, California + 25 more

Conditions: Extreme Immaturity
Interventions: Sodium chloride, Placebo; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 7 Days to 8 Days
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Alcohol Use Disorder
Interventions: Suvorexant, Placebo; Drug · Other
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Post-Traumatic Stress Disorder
Interventions: Dronabinol, Placebo; Drug
Lead sponsor: Wayne State University; Other
Eligibility: 21 Years to 45 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Infections
Interventions: E-101 Solution 300 GU/ml, Saline solution; Drug
Lead sponsor: Excited States, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 34
States / cities: Mobile, Alabama • Los Angeles, California • Stanford, California + 29 more

Conditions: Metabolic Syndrome
Interventions: intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test; Procedure · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Adult Congenital Heart Disease, Heart Failure
Interventions: Empagliflozin 10 MG, Placebo; Drug
Lead sponsor: Anita Saraf; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania

Conditions: Prediabetic State
Interventions: GlucoSupreme™ Herbal, Placebo; Dietary Supplement · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 4
States / cities: Baltimore, Maryland • Cincinnati, Ohio

Conditions: Alcoholic Hepatitis, Sepsis
Interventions: Vitamin C, Dextrose 5% in water; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Insulin Resistance
Interventions: Liraglutide, Sugar Pill; Drug
Lead sponsor: Phoenix VA Health Care System; Federal
Eligibility: 40 Years to 75 Years
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Influenza
Interventions: CR8020, CR6261, Placebo; Biological
Lead sponsor: Crucell Holland BV; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 21
States / cities: Fresno, California • Stanford, California • Washington D.C., District of Columbia + 18 more

Conditions: Prediabetes / Type 2 Diabetes
Interventions: Whey Protein Isolate Crossover, Placebo; Dietary Supplement
Lead sponsor: University of Arkansas; Other
Eligibility: 50 Years to 70 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Prediabetes
Interventions: Cocoa, Placebo; Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 40 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ 28431754, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Type 1 Diabetes Mellitus
Interventions: Pramlintide acetate, Placebo, Lispro insulin U-100, Regular insulin U-100; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Chula Vista, California • Portland, Oregon • Chattanooga, Tennessee

Conditions: Inflammation at Mini-screw Insertion Site, Mobility, Mini-screw
Interventions: Amoxicillin, Placebo oral capsule; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 12 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Lupus Nephritis (LN)
Interventions: Dapagliflozin (10Mg Tab) along with standard medical therapy, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Metabolic Syndrome X, Overweight, Hypertension, Dyslipidemias, Prediabetic State
Interventions: Placebo Comparator: First Intervention (3 weeks), Active Comparator: Second Intervention (3 weeks), Active Comparator: Third Intervention (3 weeks), Active Comparator: Fourth Intervention (3 weeks); Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 60 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Tyrosol, Creatine, Endurance Performance, Cognition, Mood
Interventions: Tyrosol, Creatine Monohydrate, Resistant Dextrin; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Fungal Infection
Interventions: Placebo, Rezafungin; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type1 Diabetes
Interventions: HCL, verapamil 120mg tablet, non-HCL, placebo; Device · Drug
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 7 Years to 17 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 6
States / cities: Palo Alto, California • Aurora, Colorado • New Haven, Connecticut + 3 more

Search by objective public record fields.

The Acute Effects of Coffee on Glucose Metabolism

Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus

Effects of Caffeine and Intermittent Hypoxia on Leg Function in Human Spinal Cord Injury

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

Sodium Supplementation and Growth in Very Low Birth Weight Infants

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

Cannabinoid Control of Fear Extinction Neural Circuits in Post-traumatic Stress Disorder

Study to Evaluate Efficacy and Safety of E-101 Solution for Preventing Surgical Site Infections After Colorectal Surgery

Insulin Sensitivity in Men With the Metabolic Syndrome

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

RCT of a Polyherbal Dietary Supplement for Prediabetes

Vitamin C Infusion for TReatment in Sepsis and Alcoholic Hepatitis

The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans

Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection

Whey Protein Ingestion and Glucose Control in Pre- and Post Diabetic Individuals

Cocoa and Metabolic Health in Prediabetes

A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus

Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

Antibiotics Prior to Mini-screw Implant Insertion

Dapagliflozin in Active Lupus Nephritis

Chloroquine to Treat People With Metabolic Syndrome Aim2 (ARCH-MS)

The Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults

Safety and Pharmacokinetics of Rezafungin

Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes